No Data
Cathie Wood's Ark Invest Is Betting Big On This AI Darling And No It's Not Nvidia
CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell?
Cathie Wood's ARK Investment Bought 133K Shares of Crispr Therapeutics Today
William Blair Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
Promising Developments and Strategic Partnerships Drive Crispr Therapeutics' Growth Potential
BofA Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $85